Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

• Published in: British journal of cancer Vol. 89; no. 7; pp. 1155 - 1158
• Main Authors: BRAUN, M. S, ADAB, F, MACMILLAN, C, SAUNDERS, M. P, COUNSELL, R, ANDERSON, H, MCDONALD, A, STEWART, J, ROBINSON, A, DAVIES, S, RICHARDS, F. J, SEYMOUR, M. T, BRADLEY, C, MCADAM, K, THOMAS, G, WADD, N. J, REA, D, PHILIPS, R, TWELVES, C, BOZZINO, J
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 06-10-2003
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Chemotherapy; Clinical; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Colorectal Neoplasms - secondary; Disease Progression; Female; Fluorouracil - administration & dosage; Humans; Leucovorin - administration & dosage; Male; Medical sciences; Middle Aged; Organoplatinum Compounds - administration & dosage; Oxaliplatin; Pharmacology. Drug treatments; Prospective Studies; Survival Rate; Time Factors; Antineoplastic agent; Intravenous administration; Colorectal cancer; Calcium folinate; Glucocorticoid; Oxaliplatin; Advanced stage; Fluorouracil; Platinum II Complexes; Human; Corticosteroid; Drug combination; Dexamethasone; Enzyme; Transferases; Fluoropyrimidine derivatives; Enzyme inhibitor; Malignant tumor; colorectal carcinoma; Thymidylate synthase; First line treatment; Colonic disease; Chemotherapy; Treatment; Methyltransferases; Antimetabolic; Digestive diseases; Pyrimidine derivatives; Fluorine Organic compounds; Therapeutic protocol
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6601237

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.